Enanta Pharma (ENTA) Tops Q2 EPS by 10c, Misses on Revenue

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.06), $0.10 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.95 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs